

*The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.*

## **The board of directors' report on events of material significance pursuant to Chapter 13, Section 6 of the Swedish Companies Act (2005:551)**

Since the board of directors<sup>1</sup> of SynAct Pharma AB, Reg. No. 559058-4826 (the "**Company**"), proposes that the extraordinary general meeting resolves on a new issue of shares in kind, the board of directors issues the following report on events of material significance.

Since the presentation of the annual report for the financial year 2021, no events of material significance for the Company's position have occurred except as set out in the Company's interim report for the period 1 January – 30 September 2022. The interim report is available at the Company's website, [www.synactpharma.com](http://www.synactpharma.com).

---

Lund on 12 December 2022

(Signature page follows)

---

<sup>1</sup> Torbjørn Bjerke and Thomas Jonassen have not participated in the board of directors' preparation of this report.

The Board of Directors of SynAct Pharma AB (publ)

Uli Hacksell

Terje Kalland

Marina Bozilenko

Kerstin Hasselgren